We are live on
!
Find out more
BCM
Boxer Capital Management Portfolio holdings
AUM
$762M
1-Year Est. Return
1,125.36%
This Fund
S&P 500
This Quarter
Est. Return
+9.43%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
–
Cap. Flow
+$1.34B
Cap. Flow
% of AUM
114.29%
Top 10 Holdings %
Top 10 Hldgs %
60.16%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$216M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$120M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$105M |
| 4 |
MRUS
Merus
MRUS
|
+$91.2M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$72.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$38.5B
| $187M | 15.94% |
+4,279,464
| New | +$216M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $124M | 10.53% |
+3,421,541
| New | +$120M |
|
|
NUVL
3
DELISTED
Nuvalent
NUVL
| $87.7M | 7.47% |
+1,120,192
| New | +$105M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $79.9M | 6.8% |
+1,900,000
| New | +$91.2M |
|
|
RNAM
5
DELISTED
Avidity Biosciences
RNAM
| $50.2M | 4.28% |
+1,727,388
| New | +$72.2M |
|
|
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
| $45.5M | 3.87% |
+1,426,000
| New | +$42.9M |
|
7
Axsome Therapeutics
AXSM
$11.7B
| $39.8M | 3.39% |
+470,000
| New | +$43.2M |
|
8
Scholar Rock
SRRK
$5.88B
| $32.4M | 2.76% |
+750,000
| New | +$24.4M |
|
9
Tango Therapeutics
TNGX
$4.21B
| $32.1M | 2.73% |
+10,380,999
| New | +$48.2M |
|
10
Tyra Biosciences
TYRA
$1.85B
| $28.2M | 2.4% |
+2,027,678
| New | +$36.8M |
|
11
Arcus Biosciences
RCUS
$3.33B
| $23.9M | 2.03% |
+1,602,200
| New | +$26.2M |
|
12
Xenon Pharmaceuticals
XENE
$6.1B
| $23.5M | 2% |
+600,000
| New | +$24.8M |
|
13
Legend Biotech
LEGN
$3.65B
| $22.8M | 1.94% |
+700,000
| New | +$29M |
|
14
Replimune Group
REPL
$454M
| $21.8M | 1.85% |
+1,796,341
| New | +$21.8M |
|
15
Geron
GERN
$898M
| $21.2M | 1.81% |
+6,000,000
| New | +$24M |
|
|
THRD
16
DELISTED
Third Harmonic Bio
THRD
| $20.6M | 1.75% |
+2,000,000
| New | +$24.9M |
|
17
Immunovant
IMVT
$7.93B
| $20.4M | 1.74% |
+825,000
| New | +$23.4M |
|
18
Arvinas
ARVN
$530M
| $20.3M | 1.73% |
+1,058,614
| New | +$25.7M |
|
|
PSTX
19
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $19.2M | 1.63% |
+2,000,000
| New | +$10.4M |
|
20
Rocket Pharmaceuticals
RCKT
$343M
| $18.4M | 1.57% |
+1,466,051
| New | +$22.1M |
|
21
AnaptysBio
ANAB
$1.54B
| $17.2M | 1.47% |
+1,300,000
| New | +$31.5M |
|
22
Kymera Therapeutics
KYMR
$8.66B
| $17.1M | 1.46% |
+425,000
| New | +$19.2M |
|
23
Enliven Therapeutics
ELVN
$3.78B
| $15.1M | 1.29% |
+671,358
| New | +$17.4M |
|
|
DAWN
24
DELISTED
Day One Biopharmaceuticals
DAWN
| $15.1M | 1.28% |
+1,189,943
| New | +$16.6M |
|
25
Oric Pharmaceuticals
ORIC
$1.17B
| $14M | 1.19% |
+1,732,571
| New | +$15.9M |
|
Similar funds
GWM
FTF
TI
CFS
PMWMG
FCA
OM
SIG
Boxer Capital Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Boxer Capital Management, which disclosed 60 positions worth $1.17B. Its ten largest holdings account for 60% of the portfolio.
Its largest position is Revolution Medicines: 4,279,464 shares worth $187M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Boxer Capital Management's largest Q4 2024 buy was Revolution Medicines: 4,279,464 shares worth $187M.
- Boxer Capital Management's ten largest holdings make up 60% of its $1.17B portfolio in Q4 2024.
- Boxer Capital Management disclosed 60 positions in Q4 2024, its first 13F filing on record.
Based on Boxer Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.